ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK

This study is currently recruiting participants.
Verified by Walter Reed Army Medical Center, June 2008

Sponsors and Collaborators: Walter Reed Army Medical Center
Schepens Eye Research Institute
Information provided by: Walter Reed Army Medical Center
ClinicalTrials.gov Identifier: NCT00411827
  Purpose

Purpose: To develop a screening metric by examining both the characteristics of the preoperative tear film and the intracellular signaling pathways of conjunctival goblet cells in order to determine if there are certain characteristics which might predict those patients who will experience serious dry eye symptoms and complications after refractive surgery.

Research Design: This study is a twelve-month prospective non-randomized investigation.

Methodology: In conjunction with psychometric questionnaires and various measures of tear film quality (e.g. Schirmer's test, tear break up time, etc), impression cytology will be used to assess the intracellular signaling pathways of conjunctival goblet cells and to determine if alterations in this pathway exist. Alterations in this pathway would result in a reduced response by the mucin secreting conjunctival goblet cells thereby promoting the development of dry eye after refractive surgery.


Condition Intervention
Keratoconjunctivitis Sicca
Procedure: conjunctival impression cytology

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment
Official Title:   Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK

Further study details as provided by Walter Reed Army Medical Center:

Primary Outcome Measures:
  • Dry eye [ Time Frame: one year after surgery ] [ Designated as safety issue: No ]

Estimated Enrollment:   146
Study Start Date:   January 2008
Estimated Study Completion Date:   December 2009
Estimated Primary Completion Date:   December 2009 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Active Comparator
PRK
Procedure: conjunctival impression cytology
conjunctival impression cytology
2: Active Comparator
LASIK
Procedure: conjunctival impression cytology
conjunctival impression cytology

  Eligibility
Ages Eligible for Study:   21 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

Subjects will be recruited from those active duty soldiers that have requested refractive surgery. Subjects must be eligible for medical care at WRAMC.

  1. Male or female, of any race, and at least 21 years old and not older than 40 years old at the time of the pre-operative examination, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability and is the minimal age required by the FDA for informed consent for LASIK surgery.
  2. Manifest refractive spherical equivalent (MSE) of up to 10.00 diopters at the spectacle plane with refractive cylinder up to 3.00 D.
  3. Best spectacle corrected visual acuity of 20/20 or better in both eyes.
  4. Patients who are willing to fill out dry eye questionnaires.
  5. Demonstrated refractive stability, confirmed by clinical records. Neither the spherical nor the cylindrical portion of the refraction may have changed more than 0.50D during the 12- month period immediately preceding the baseline examination, as confirmed by clinical records.
  6. All patients must be willing to return to the WRAMC Center for Refractive Surgery for follow up visits on Day1, Day 3, Day 7, and 1, 3, 6, and 12 months after their surgery.
  7. Located in the greater Washington DC area for a 14-month period.
  8. Consent of the subject's command (active duty) to participate in the study.
  9. Access to transportation to meet follow-up requirements.

Exclusion Criteria:

  1. Previous surgery or trauma to the study eye.
  2. Dry eye as reflected by Schirmer's test with anesthesia of 0, subjective complaints or symptoms of dry eye, findings during the slit lamp exam that would be consistent with dry eye (e.g. superficial punctuate keratitis).
  3. Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. This is a standard of care exclusion for refractive surgery at the Walter Reed Refractive Surgery Center because of the medications that are routinely given as part of the procedures. Standard of care analgesia consists of medications (e.g. narcotics) labeled as Pregnancy Category "C" by the FDA. Teratogenic effects are not known, however, physical dependence in the neonate may occur if the mother is given narcotics. Female subjects will be given a urine pregnancy test prior to participating in the study to rule out pregnancy.
  4. Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatriptan (Imitrex).
  5. Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.
  6. Active ophthalmic disease, neovascularization of the cornea within 1mm of the intended ablation zone, or clinically significant lens opacity.
  7. Evidence of glaucoma or an intraocular pressure greater than 22 mm Hg at baseline.
  8. Evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye.
  9. History of recurrent erosions or epithelial basement dystrophy.
  10. Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course.
  11. Any physical or mental impairment that would preclude participation in any of the examinations.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00411827

Contacts
Contact: KRAIG BOWER, MD     202.782.0202     kraig.bower@na.amedd.army.mil    

Locations
United States, District of Columbia
Walter Reed Army Medical Center     Recruiting
      Washington, District of Columbia, United States, 20307
      Contact: Lamarr Peppers, BA     202-782-7862     lamarr.peppers@amedd.army.mil    

Sponsors and Collaborators
Walter Reed Army Medical Center
Schepens Eye Research Institute

Investigators
Principal Investigator:     KRAIG S BOWER, MD     WRAMC    
  More Information


Study ID Numbers:   WRAMC WU#06-23014
First Received:   December 13, 2006
Last Updated:   June 25, 2008
ClinicalTrials.gov Identifier:   NCT00411827
Health Authority:   United States: Federal Government

Keywords provided by Walter Reed Army Medical Center:
Cytology  
Keratomileusis, Laser In Situ  
Keratectomy, Photorefractive, Excimer Laser  

Study placed in the following topic categories:
Corneal Diseases
Keratoconjunctivitis sicca
Xerophthalmia
Eye Diseases
Lacrimal Apparatus Diseases
Keratitis
Dry Eye Syndromes
Conjunctivitis
Keratoconjunctivitis
Conjunctival Diseases
Keratoconjunctivitis Sicca

ClinicalTrials.gov processed this record on October 15, 2008




Links to all studies - primarily for crawlers